[October 20, 2014]

Research and Markets: Japan HER2-Positive Breast Cancer Drug Forecast and Market Analysis to 2023 - Herceptin is the Market Leader, Taking 92% of the Market in 2013

Research and Markets (http://www.researchandmarkets.com/research/4td5fg/pharmapoint) has announced the addition of the "PharmaPoint: HER2-Positive Breast Cancer - Japan Drug Forecast and Market Analysis to 2023" report to their offering.

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

In 2013, Herceptin was the market leader, taking 92% of the Japanese market. This is due to the fact that it is the most established agent in this disease and is used in all settings, although over half of all Herceptin use is in the adjuvant setting.

Key Topcs Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

• Etiology and Pathophysiology
• Basic Breast Anatomy
• Breast Cancer Staging
• Prognosis (News - Alert)
• Quality of Life
• Symptoms

4 Disease Management

• Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB)
• Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA)
• Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV)

5 Competitive Assessment

Product Profiles - HER2-Targeted Therapies

• Herceptin (trastuzumab)
• Tykerb (lapatinib)
• Perjeta (pertuzumab)
• Kadcyla (ado-trastuzumab emtansine, T-DM1)

Product Profiles - General Targeted Therapies

• Afinitor (everolimus)
• Xeloda (capecitabine)
• Avastin (bevacizumab)
• Halaven (eribulin mesylate)
• Abraxane (nab-paclitaxel)

Hormonal Agents

• Tamoxifen
• Faslodex (fulvestrant)
• Aromatase Inhibitors

6 Unmet Need and Opportunity

• Brain Metastases
• Resistance to HER2-Targeting Therapies

7 Pipeline Assessment

Promising Drugs in Clinical Development

• Gilotrif (afatinib)
• Neratinib

Promising Drugs in Early-Stage Development

• Palbociclib
• NeuVax (nelipepimut-S)
• Patritumab
• Ganetespib
• ARRY-380 (ONT-380)
• NVP-BYL719

Biosimilars

8 Market Outlook

• Forecast
• Key Events
• Drivers and Barriers

9 Appendix

For more information visit http://www.researchandmarkets.com/research/4td5fg/pharmapoint

[ Back To TMCnet.com's Homepage ]